Purple Biotech announces publication of study on potential of NT219

Purple Biotech (PPBT) announced the publication of an independent study titled “IRS2 as a driver of brain metastasis in colorectal cancer: a potential target for novel therapeutic strategies” in the peer reviewed journal, Neuro Oncology. NT219 is a first-in-class small molecule drug designed to target key cancer resistance mechanisms by degrading IRS1/2 and blocking downstream signaling towards AKT and b-catenin, as well as STAT3 survival pathways. “These compelling findings suggest a potential opportunity to make a significant impact on prolonging the life of colorectal cancer patients, approximately 20% of whom have distant metastasis at diagnosis, with another 50% developing metastasis at a later stage,” stated Gil Efron, Purple Biotech CEO. “We are currently advancing NT219 into a Phase 2 study in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck a and may pursue additional opportunities to expand the clinical development of NT219 in colorectal and other cancers, leveraging its novel mechanism of action.”